Gamco Investors INC. ET AL cut its position in Chemed Corp. (NYSE:CHE) by 6.7% during the second quarter, Holdings Channel reports. The fund owned 556,484 shares of the company’s stock after selling 40,016 shares during the period. Gamco Investors INC. ET AL’s holdings in Chemed Corp. were worth $113,818,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. boosted its position in Chemed Corp. by 145,760.9% in the first quarter. BlackRock Inc. now owns 1,955,994 shares of the company’s stock worth $357,341,000 after buying an additional 1,954,653 shares during the last quarter. Vanguard Group Inc. boosted its position in Chemed Corp. by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,795,773 shares of the company’s stock worth $328,070,000 after buying an additional 125,018 shares during the last quarter. State Street Corp boosted its position in Chemed Corp. by 9.1% in the first quarter. State Street Corp now owns 445,367 shares of the company’s stock worth $81,370,000 after buying an additional 37,085 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in Chemed Corp. during the first quarter worth approximately $4,445,000. Finally, Neuberger Berman Group LLC boosted its position in Chemed Corp. by 2.2% in the first quarter. Neuberger Berman Group LLC now owns 1,060,403 shares of the company’s stock worth $193,725,000 after buying an additional 23,306 shares during the last quarter. Hedge funds and other institutional investors own 97.78% of the company’s stock.
Shares of Chemed Corp. (CHE) opened at 191.17 on Thursday. Chemed Corp. has a 1-year low of $130.05 and a 1-year high of $216.01. The company has a 50-day moving average of $200.36 and a 200-day moving average of $192.63. The stock has a market capitalization of $3.06 billion, a price-to-earnings ratio of 47.42 and a beta of 1.14.
Chemed Corp. (NYSE:CHE) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $2.15 EPS for the quarter, topping the Zacks’ consensus estimate of $1.89 by $0.26. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The business had revenue of $415.06 million during the quarter, compared to the consensus estimate of $407.56 million. During the same period in the previous year, the company posted $1.80 earnings per share. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, equities research analysts expect that Chemed Corp. will post $8.20 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Monday, August 14th will be given a dividend of $0.28 per share. The ex-dividend date is Thursday, August 10th. This is an increase from Chemed Corp.’s previous quarterly dividend of $0.26. This represents a $1.12 dividend on an annualized basis and a dividend yield of 0.59%. Chemed Corp.’s payout ratio is currently 28.07%.
CHE has been the topic of a number of research analyst reports. BidaskClub cut shares of Chemed Corp. from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 22nd. Zacks Investment Research cut shares of Chemed Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Royal Bank Of Canada restated a “hold” rating and issued a $208.00 price target on shares of Chemed Corp. in a report on Wednesday, July 5th. Oppenheimer Holdings, Inc. upped their price target on shares of Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. Finally, TheStreet cut shares of Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $218.33.
In related news, Director George J. Walsh III acquired 1,000 shares of the stock in a transaction dated Monday, June 26th. The stock was acquired at an average cost of $204.56 per share, with a total value of $204,560.00. Following the completion of the transaction, the director now owns 7,908 shares in the company, valued at approximately $1,617,660.48. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Kevin J. Mcnamara sold 15,000 shares of the business’s stock in a transaction dated Friday, July 28th. The stock was sold at an average price of $201.16, for a total value of $3,017,400.00. Following the transaction, the insider now directly owns 173,801 shares of the company’s stock, valued at $34,961,809.16. The disclosure for this sale can be found here. Insiders own 5.32% of the company’s stock.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.